Tiny Health Secures $33 Million Series B Led by B Capital

Tiny Health announced a $33 million Series B funding round led by B Capital. The financing brings the Austin-based microbiome intelligence platform's total funding to $46 million. Existing investors Spero Ventures, The Venture City, and Overwater Ventures participated. New investors in the round include Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels, and Pari Passu Ventures.

Company background and leadership

Cheryl Sew Hoy founded Tiny Health in 2020 after her son's birth. Nick Whitehead, a Senior Principal at lead investor B Capital, will join the company's Board of Directors. The leadership team also includes chief science officer Kimberley Sukhum, who joined in 2021, and chief medical officer Dr. Elisa Song, an integrative pediatrician. Co-founder Donald Koo leads technology work after joining Sew Hoy two years after she started the company.

Product offering and market traction

Tiny Health serves nearly 200,000 customers and more than 6,000 healthcare practitioners, offering training on using its tests in patient care. The company provides at-home microbiome tests for pregnancy, vaginal health, and adults. Adults have become the company's largest testing segment, moving beyond its initial focus on infants. Customers collect a small stool sample with a swab and send it for analysis.

The tests use shotgun metagenomic sequencing, a method described as the gold standard, to analyze microbial DNA. The platform detects microbes across more than 120,000 genomes down to the strain level. It surfaces insights about metabolic capacity, immune markers, and pathogenic organisms. After analysis, customers receive a report on detected microbes with explanations and suggested next steps. The company also sells a subscription service called Tiny Plus that includes a baseline test and a retest.

Practitioners served span independent practices, hospital systems, longevity clinics, consumer health companies, and precision medicine organizations.

Growth and business expansion

Tiny Health's overall revenue has more than doubled each year, according to Sew Hoy. The company's fastest-growing segment is its B2B arm, called Powered by Tiny, which grew fourfold last year. This enterprise business sells testing through healthcare providers and other companies via technology integrations.

Partners of Powered by Tiny include Superpower, Fullscript, and Mayo Clinic’s Executive Health and Longevity Programs. The company also collaborates with supplement makers and academic partners to measure the microbiome in clinical studies. Other partners include Joi + Blokes, Resbiotic, Siphox, Nia Health, and Allina Health.

The company intends to use the new capital to scale the Powered by Tiny platform. Funds will also advance clinical research and interventional studies, expand healthcare practitioner education, and accelerate the development of TinyAI.

Research commitment and platform capabilities

Tiny AI is an artificial intelligence system trained on the company's proprietary dataset of nearly 200,000 microbiome profiles. It is designed to deliver personalized, science-backed guidance tied directly to a user's results. The testing platform reveals whether a microbiome is trending toward resilience or imbalances.

To further its scientific goals, Tiny Health is committing $5 million to a Microbiome Research Program. This program will enable researchers, clinicians, and scientific partners to leverage the company's testing, data, and research capabilities. The aim is to investigate important intervention strategies in microbiome health.

The company collaborates with academic institutions including Stanford Medicine, Mayo Clinic, and Massachusetts General Hospital. The Series B funds will advance clinical research and interventional studies, expand practitioner education, scale Powered by Tiny, and accelerate TinyAI development.